RESUMO
To evaluate corneal endothelial cell changes after intravitreal and subconjunctival injection of avastin [bevacizumab] based on specular microscopic findings. This prospective interventional study was performed on 82 eyes of 82 patients. Forty-two cases with ptrygia received a subconjunctival injection of bevacizumab [2.5mg/0.2ml] and 40 diabetic subjects with retinal neovascularization or macular edema received an intravitreal injection of bevacizumab [1.25mg/0.1ml]. Specular microscopy, including corneal endothelial cell count, size and shape, was performed in all patients for the injected eye before, and one and three month after injection and the results were compared and analyzed. There was no change in the corneal endothelial cells count after one month but there was mild reduction of endothelial cells after 3 months which was not statistically significant.[P=0.75 and 0.29, respectively]. Subconjunctival and intravitreal injection of bevacizumab [up to 1.25 mg/0.1 ml and 2.5 mg/0.2 ml, respectively] entails no harmful effect on human corneal endothelial cells up to three months following the injection